Merck & Co's cancer drug Keytruda has been granted a priority review so that the immunotherapy medicine can be used in conjunction with chemotherapy to improve survival rates for untreated lung cancer. The US Food and Drug Administration (FDA)...
Original Article: Keytruda combo gets fast review in untreated lung cancer